KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $35.8 billion.

  • Regeneron Pharmaceuticals' Retained Earnings rose 1302.12% to $35.8 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $35.8 billion, marking a year-over-year increase of 1302.12%. This contributed to the annual value of $35.8 billion for FY2025, which is 1302.12% up from last year.
  • As of Q4 2025, Regeneron Pharmaceuticals' Retained Earnings stood at $35.8 billion, which was up 1302.12% from $35.0 billion recorded in Q3 2025.
  • Over the past 5 years, Regeneron Pharmaceuticals' Retained Earnings peaked at $35.8 billion during Q4 2025, and registered a low of $12.0 billion during Q1 2021.
  • Moreover, its 5-year median value for Retained Earnings was $25.6 billion (2023), whereas its average is $25.4 billion.
  • As far as peak fluctuations go, Regeneron Pharmaceuticals' Retained Earnings surged by 7413.29% in 2021, and later soared by 1302.12% in 2025.
  • Quarter analysis of 5 years shows Regeneron Pharmaceuticals' Retained Earnings stood at $19.0 billion in 2021, then rose by 22.87% to $23.3 billion in 2022, then grew by 16.96% to $27.3 billion in 2023, then rose by 16.19% to $31.7 billion in 2024, then increased by 13.02% to $35.8 billion in 2025.
  • Its last three reported values are $35.8 billion in Q4 2025, $35.0 billion for Q3 2025, and $33.7 billion during Q2 2025.